Blog
  by

Leading Biotech Companies Use Precision Medicine to Target Cancer

Summary: Three biotech companies are targeting a single genetic mutation in cancer cells to shrink solid tumors. For more information and a link to Sg2 expertise on preparing for precision medicine, read on.

A recent Investor’s Business Daily article highlights 3 biotech companies aiming to shrink solid tumors by targeting a single genetic mutation in cancer cells. The research is in its infancy (none of the 3 biotech companies currently has sales from approved drugs), but the implications of designing treatment regimens beyond the scope of chemotherapy could revolutionize oncologists’ medical practices and potentially improve patient survival rates.

Recently, providers, researchers and health care executives converged for the annual American Society of Clinical Oncology (ASCO) meeting, where precision medicine was a dominant topic. This year’s theme of “Delivering Discoveries: Expanding the Reach of Precision Medicine” was about self-reflection: recognizing that the path to precision medicine is well under way, acknowledging that real challenges and gaps persist, and identifying a way forward.

Sg2 encourages its members to evaluate and challenge the utility of precision medicine, especially as this care trend continues to gain national attention. To learn more about how precision medicine is redefining care delivery and the action steps that can help prepare for this rapidly changing field, read the Sg2 Expert Insight ASCO 2018: Back to the Future (of Precision Medicine).

  • Share
  • Follow Sg2 on Facebook
  • Follow Sg2 on Twitter
  • Connect with Sg2 on LinkedIn
"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube